by admin | Dec 16, 2021 | Press Releases
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. 
by admin | Feb 26, 2019 | Press Releases
Anaveon, an immuno-oncology company, today announced completion of a CHF 35 million Series A financing led by Syncona Ltd and joined by the Novartis Venture Fund. 
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023